Welcome to Open Science
Contact Us
Home Books Journals Submission Open Science Join Us News Unsubscribe Page
Neuroprotective and Antinociceptive Activity of Two New Derivatives of Deoxypeganine Alkaloid
Current Issue
Volume 3, 2015
Issue 5 (October)
Pages: 56-60   |   Vol. 3, No. 5, October 2015   |   Follow on         
Paper in PDF Downloads: 32   Since Sep. 8, 2015 Views: 852   Since Sep. 8, 2015
Authors
[1]
Firuza Tursunkhodjaeva, Institute of the Chemistry of Plant Substances Named after Academician S. Yu. Yunusov, Sciences Academy of the Republic of Uzbekistan, Tashkent, Uzbekistan.
[2]
Nurkhon Sokhibova, Institute of the Chemistry of Plant Substances Named after Academician S. Yu. Yunusov, Sciences Academy of the Republic of Uzbekistan, Tashkent, Uzbekistan.
Abstract
Deoxypeganine alkaloid isolated from Peganum harmala L. is well known as a reversible acetylcholinesterase inhibitor. Further investigations showed its effectiveness in treatment of drug and nicotinic addictions and alcoholism, Alzheimer dementia, clinic depression, schizophrenia and chronic fatigue, poisoning by psychotrops. In the present investigation we revealed the neuroprotective activity of deoxypeganine and two its amino derivatives on two animal models. In the first series of experiments deoxypeganine and its derivatives were injected to mice intraperitoneally, in 15 minutes nicotine-base introduced subcutaneously, in 30 minutes the animals were placed in the central compartment of 12-compartement maze, and their exploratory activity effectiveness monitored. In the second series of experiments we used atropine sulfate instead of nicotine. The test proceeding was the same. Both amino derivatives were more potent in mice cognitive functions improvement than deoxypeganine and galantamine that indicates the necessity of their further investigation. Experiments in analgesic activity assessment in acetic writhing and hot plate tests have shown the lack of antinociceptive responses to pain in the centrally mediated analgesia (hot plate) test for deoxypeganine and its derivatives, while galantamine shown relatively high analgesia. In the acetic writhing test deoxypeganine and its derivatives were potent, but in a less extent than galantamine. Relatively high analgesic effect of galantamine may possibly be attributed to the involvement of “hypophysis - glucocorticoids” axis. Anti-inflammatory effects of all investigated derivatives in formalin rat test were low, although their ability to shorten the recovery period in inflammation attracts the special attention and needs further investigation.
Keywords
Deoxypeganine, 6-Aminodeoxypeganine, 6,8-Diaminodeoxypeganine, Cognitive Functions, Analgesic, Anti-Inflammatory
Reference
[1]
Tulyaganov N, Sadriddinov F, Suleymanova G. The pharmacological characteristics of deoxypeganine hydrochloride. J. Pharmacol. and Toxicol. (Moscow) 1986; 49 (3): 37-40.
[2]
Asmussen B, Hille T, Hoffmann HR, Opitz K. Pharmaceutical composition containing deoxypeganine for the treatment of nicotine dependence. United States Patent No.6,548,510 B1, 2003.
[3]
Asmussen B, Hille T., Hoffmann HR, Opitz K. Pharmaceutical composition containing deoxypeganine for the treatment of alcoholism. United States Patent No.6,627,631 B1, 2003.
[4]
Asmussen B, Hille T, Hoffmann HR, Opitz K. Pharmaceutical composition containing deoxypeganine for the treatment of drug dependence. United States Patent No.6,599,511 B1, 2003.
[5]
Asmussen B, Hille T, Hoffmann HR, Opitz K. Use of deoxypeganine in the treatment of Alzheimer’s dementia. United States Patent No.6,436,937 B1, 2002.
[6]
Moormann J, Mucke H. Use of deoxypeganine for treating clinical depression. United States Patent Application Publication No. US 2005/0009813 A1, 2005.
[7]
Moormann J, Opitz K, Hoffmann HR. Oral formulations of deoxypeganine and thereof uses. United States Patent Application Publication No. US 2007/0155774 A1, 2007.
[8]
Opitz K, Moormann J, Hille T, Becher F. Use of deoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops. United States Patent Application Publication No. US 2004/0132751 A1, 2004.
[9]
Mishra D, Ghosh G, Kumar S, Panda PK. An experimental study of analgesic activity of selective COX-2 inhibitor with conventional NSAIDs. Asian J. of Pharm. and Clin. Res. 2011; 4 (1): 78-81.
[10]
Wheeler-Aceto H, Cowan A. Standardization of the rat paw formalin test for the evaluation of analgesics. Psychopharmacology (Berl). 1991; 104(1): 35-44.
[11]
Winters BD, Saksida LM, Bussey TJ. Paradoxical facilitation of object recognition memory after infusion of scopolamine into perirhinal cortex: implications for cholinergic system function. J. of Neuroscience 2006; 26 (37): 9520-9.
[12]
Salimov R, Salimova N, Shvets L, Shvets N. Effect on chronic piracetam on age-related changes of cross-maze exploration in mice. Pharmacol. Biochem. Behav. 1995; 52 (3): 637-40.
[13]
Cummings J. Cholinesterase inhibitors: a new class of psychotropic compounds. The American J. of Psychiatry 2000; 157 (1): 4-15.
[14]
Martikainen IK. Brain dopamine and serotonin receptors in the perception of pain. Positron emission tomography studies in healthy subjects. Turun Yliopisto, University of Turku, Turku. 2009.
Open Science Scholarly Journals
Open Science is a peer-reviewed platform, the journals of which cover a wide range of academic disciplines and serve the world's research and scholarly communities. Upon acceptance, Open Science Journals will be immediately and permanently free for everyone to read and download.
CONTACT US
Office Address:
228 Park Ave., S#45956, New York, NY 10003
Phone: +(001)(347)535 0661
E-mail:
LET'S GET IN TOUCH
Name
E-mail
Subject
Message
SEND MASSAGE
Copyright © 2013-, Open Science Publishers - All Rights Reserved